COMPOSITIONS AND METHODS FOR THE EARLY DIAGNOSIS OF OVARIAN CANCER

Abstract: The disclosed nucleic acid primer sets, used in combination with quantitative amplification (PCR) of tissue cDNA, can indicate the presence of specific proteases in a tissue sample. The detected proteases are themselves specifically overexpressed in certain cancers, and the presence of their genetic precursors may serve for early detection of associated ovarian and other malignancies, and for the design of interactive therapies for cancer treatment.

Description: COMPOSITIONS AND METHODS FOR THE EARLY DIAGNOSIS OF OVARIAN CANCER BACKGROUND OF THE INVENTION Field of the Invention Generally, the present invention relates to the fields o f molecular biology and medicine. More specifically, the present invention is in the field of cancer, especially ovarian cancer diagnosis. Background of the Invention To date, ovarian cancer remains the number one killer o f women with gynecologic malignant hyperplasia. Approximately 75 % of women diagnosed with such cancers are already at an advanced stage (III and IV) of the disease at their initial diagnosis. During the past 20 years, neither diagnosis nor five year survival rates have greatly improved for these patients. This is substantially due to th e high percentage of high-stage initial detections of the disease. Therefore, the challenge remains to develop new markers th at improve early diagnosis and thereby reduce the percentage of high- stage initial diagnoses. Extracellular proteases have already been implicated in the growth, spread and metastatic progression of many cancers, du e to the ability of malignant cells not only to grow in situ, but t o dissociate from the primary tumor and to invade new surfaces. The ability to disengage from one tissue and re-engage the surface o f another tissue is what provides for the morbidity and mortality associated with this disease. Therefore, extracellular proteases may be good candidates for markers of neoplastic development. In order for malignant cells to grow, spread o r metastasize, they must have the capacity to invade local host tissue, dissociate or shed from the primary tumor, and for metastasis t o occur, enter and survive in the bloodstream, implant by invasion into the surface of the target organ and establish an environment conducive for new colony growth (including the induction o f angiogenic and growth factors). During this progression, natural tissue barriers have to be degraded, including basement membranes and connective tissue. These barriers include collagen, laminin, proteoglycans and extracellular matrix glycoproteins, including fibronectin. Degradation of these natural barriers, both tho se surrounding the primary tumor and at the sites of metastatic invasion, is believed to be brought about by the action of a matrix o f extracellular proteases. Proteases have been classified into four families: serine proteases, metallo-proteases, aspartic proteases and cysteine proteases. Many proteases have been shown to be involved in the human disease process and these enzymes are targets for th e development of inhibitors as new therapeutic agents. Additionally, certain individual proteases have been shown to be induced and overexpressed in a diverse group of cancers, and as such, are potential candidates for markers of early diagnosis and possible therapeutic intervention. A group of examples are shown in Table 1. TABT F 1 Known proteases expressed in various cancers Gastric Brain Breast Ovarian Serine Proteases: uPA uPA NES-1 NES-1 PAI-1 PAI-1 uPA uPA tPA PAI-2 Cysteine Proteases: Cathepsin B Cathepsin L Cathepsin B Cathepsin B Cathepsin L Cathepsin L Cathepsin L Metallo-proteases : Matrilysin* Matrilysin Stromelysin-3 MMP-2 Collagenase* Stromelysin MMP-8 Stromelysin-1* Gelatinase B MMP-9 Gelatinase A uPA, Urokinase-type plasminogen activator; tPA, Tissue-type plasminogen activator; PAI-I, Plasminogen activator 0 inhibitors; PAI- 2, Plasminogen activator inhibitors; NES-1, Normal epithelial cell- specific- 1 ; MMP, Matrix P metallo-protease. *Overexpressed i n gastrointestinal ulcers. Significantly, there is a good body of evidence supporting the downregulation or inhibition of individual proteases and the reduction in invasive capacity or malignancy. In work b y Clark et al. , inhibition of in vitro growth of human small cell lung cancer was demonstrated using a general serine protease inhibitor. More recently, Torres-Rosedo et al., [Proc. Natl.Acad.Sci. USA, 90 , 7181-7185 (1993)] demonstrated an inhibition of hepatoma tumor cell growth using specific antisense inhibitors for the serine protease hepsin gene. Metastatic potential of melanoma cells has also been shown to be reduced in a mouse model using a synthetic inhibitor (batimastat) of metallo-proteases. Powell et al. [Cancer Research, 53, 417-422 (1993)] presented evidence to confirm that the expression of extracellular proteases in relatively non-invasive tumor cells enhances their malignant progression using a tumorgenic, but non-metastatic, prostate cell line. Specifically, enhanced metastasis was demonstrated after introducing an d expressing the PUMP-1 metallo-protease gene. There is also a body of data to support the notion that expression of cell surface proteases on relatively non-metastatic cell types increases th e invasive potential of such cells. Thus, the prior art is deficient in a tumor marker useful as an indicator of early disease, particularly for ovarian cancers . The present invention fulfills this long-standing need and desire in the art. SUMMARY OF THE INVENTION This invention allows for the detection of cancer, especially ovarian cancer, by screening for hepsin mRNA in tissue, which is indicative of the hepsin protease, which is shown herein t o be specifically associated with the surface of 80 percent of ovarian and other tumors. Proteases are considered to be an integral part o f tumor growth and metastasis, and therefore, markers indicative o f their presence or absence are useful for the diagnosis of cancer. Furthermore, the present invention is useful for treatment (i. e., b y inhibiting hepsin or expression of hepsin), for targeted therapy, for vaccination, etc. In one embodiment of the "present invention, there is provided a method of diagnosing cancer in an individual, comprising the steps of obtaining a biological sample from an individual an d detecting hepsin in the sample. The presence of hepsin in the sample is indicative of the presence of carcinoma in the individual, wherein the absence of hepsin in the sample is indicative of the absence of carcinoma in the individual. In another embodiment of the present invention, there is provided a method for detecting malignant hyperplasia in a biological sample, comprising the steps of isolating mRNA from th e sample; and detecting hepsin mRNA in the sample. The presence o f the hepsin mRNA in the sample is indicative of the presence o f malignant hyperplasia, and the absense of the hepsin mRNA in th e sample is indicative of the absence of malignant hyperplasia. In yet another embodiment of the present invention, there is provided a method for detecting malignant hyperplasia in a biological sample, comprising the steps of isolating protein from th e sample; and detecting hepsin protein in the sample. The presence o f the hepsin protein in the sample is indicative of the presence o f malignant hyperplasia, wherein the absense of the hepsin protein in the sample is indicative of the absence of malignant hyperplasia. This method may further comprise the step of comparing the hepsin protein to reference information, wherein the comparison provides a diagnosis of the malignant hyperplasia, or alternatively, determines a treatment of the malignant hyperplasia. In still yet another embodiment of the present invention, there is provided a method of inhibiting expression of hepsin in a cell, comprising the step of introducing a vector into a cell, wherein the vector comprises a hepsin gene in opposite orientation operably linked to elements necessary for expression. Expression of the vector produces hepsin antisense mRNA in the cell, which hybridizes to endogenous hepsin mRNA and thereby inhibits expression o f hepsin in the cell. In yet another embodiment of the present invention, there is provided a method of inhibiting a hepsin protein in a cell, comprising the step of introducing an antibody specific for a hepsin protein or a fragment thereof into a cell. Binding of the antibody inhibits the hepsin protein. In another embodiment of the present invention, there is provided a method of targeted therapy to an individual, comprising the step of administering a compound to an individual, wherein th e compound has a targeting moiety and a therapeutic moiety, wherein the targeting moiety is specific for hepsin. In yet another embodiment of the present invention, there is provided a method of vaccinating an individual against hepsin, comprising the steps of inoculating an individual with a hepsin protein or fragment thereof, wherein the hepsin protein o r fragment thereof lack hepsin protease activity. Inoculation with th e hepsin protein or fragment thereof elicits an immune response in the individual, thereby vaccinating the individual against hepsin. In still another embodiment of the present invention, there is provided an oligonucleotide having a sequence complementary to SEQ ID No.188. Also embodied is a composition comprising the above-described oligonucleotide and a physiologically acceptable carrier therefore. Additionally embodied is a method of treating a neoplastic state in an individual in need o f such treatment, comprising the step of administering to th e individual an effective dose of the above-described oligonucleotide. In another embodiment of the present invention, there is provided a method of screening for compounds that inhibit hepsin activity, comprising the steps of contacting a sample with a compound, wherein the sample comprises hepsin protein; and assaying for hepsin protease activity. A decrease in the hepsin protease activity in the presence of the compound relative to hepsin protease activity in the absence of the compound is indicative of a compound that inhibits hepsin activity. Other and further aspects, features, and advantages o f the present invention will be apparent from the following description of the presently preferred embodiments of the invention. These embodiments are given for the purpose o f disclosure. BRIEF DESCRIPTION OF THE DRAWINGS The appended drawings have been included herein s o that the above-recited features, advantages and objects of th e invention will become clear and can be understood in detail. These drawings form a part of the specification. It is to be noted , however, that the appended drawings illustrate preferred embodiments of the invention and should not be considered to limit the scope of the invention. Figure 1 shows agarose gel comparison of PCR products derived from normal and carcinoma cDNA. Figure 2 shows Northern blot analysis of ovarian tumors using hepsin, SCCE, PUMP-1, TADG-14 and β-tubulin probes. Figure 3 shows amplification with serine protease redundant primers: histidine sense (S I) with aspartic acid antisense (AS1), using normal cDNA (Lane 1) and tumor cDNA (Lane 2); an d histidine sense (S I) with serine antisense (AS2), using normal cDNA (Lane 3) and tumor cDNA (Lane 4). Figure 4 shows amplification with cysteine protease redundant primers. Normal (Lane 1), low malignant potential (Lane 2), serious carcinoma (Lane 3), mucinous carcinoma (Lane 4), an d clear cell carcinoma (Lane 5). Figure 5 shows amplification with metallo-protease redundant primers. Normal (Lane 1), low malignant potential (Lane 2), serious carcinoma (Lane 3), mucinous carcinoma (Lane 4), an d clear cell carcinoma (Lane 5). Figure 6 shows amplification with specific primers directed towards the serine protease, hepsin. Expression in normal (Lanes 1-3), low malignant potential tumors (Lanes 4-8), and ovarian carcinomas (Lanes 9- 12). Figure 7 shows hepsin expression levels in normal, low malignant potential tumors, and ovarian carcinomas. S=serious, M=mucinous, LMP=low malignant potential. Figure 8 shows serine protease stratum corneum chymotrypsin enzyme (SCCE) expression in normal, low malignant potential tumors, and ovarian carcinomas. Figure 9 shows metallo-protease PUMP-1 (MMP-7) gene expression in normal (lanes 1-2) and ovarian carcinomas tissue (Lanes 3-10). Figure 10 A shows Northern blot analysis of hepsin expression in normal ovary and ovarian carcinomas. Lane 1 , normal ovary (case 10); lane 2 , serous carcinoma (case 35); lane 3, mucinous carcinoma (case 48); lane 4, endometrioid carcinoma (case 51); and lane 5 , clear cell carcinoma (case 54). In cases 35 , 51 and 54, more than a 10-fold increase in the hepsin 1.8 k b transcript abundance was observed. Figure 10B shows Northern blot analysis of hepsin in normal human fetal. Figure 10C shows Northern blot analysis of hepsin in adult tissues. Significant overexpression of the hepsin transcript is noted in both fetal liver and fetal kidney. Notably, hepsin overexpression is not observed in normal adult tissue. Slight expression above the background level is observed in the adult prostate. Figure 11A shows hepsin expression in normal (N) , mucinous (M) and serous (S) low malignant potential (LMP) tumors and carcinomas (CA). β-tubulin was used as an internal control . Figure 11B shows the ratio of hepsin: β-tubulin expression in normal ovary, LMP tumor, and ovarian carcinoma. Hepsin mRNA expression levels were significantly elevated in LMP tumors, (p < 0.005) and carcinomas (p < 0.0001 ) compared to levels in normal ovary. All 10 cases of normal ovaries showed a relatively low level of hepsin mRNA expression. Figure 12 A shows northern blot analysis of mRNA expression of the SCCE gene in fetal tissue. Figure 12B shows northern blot analysis of mRNA expression of the SCCE gene in ovarian tissue. Figure 13A shows a comparison of quantitative PCR o f SCCE cDNA from normal ovary and ovarian carcinomas. Figure 13B shows a bar graph comparing the ratio of SCCE to β-tubulin in 10 normal and 44 ovarian carcinoma tissues. Figure 14 shows a comparison by quantitative PCR o f normal and ovarian carcinoma expression of mRNA for protease M. Figure 15 shows the TADG-12 catalytic domain including an insert near the His 5'-end. Figure 16 A shows northern blot analysis comparing TADG-14 expression in normal and ovarian carcinoma tissues . Figure 16B shows preliminary quantitative PCR amplification o f normal and carcinoma cDNAs using specific primers for TADG-14. Figure 17 A shows northern blot analysis of the PUMP-1 gene in human fetal tissue. Figure 17B shows northern blot analysis of the PUMP-1 gene in normal ovary and ovarian carcinomas . Figure 18A shows a comparison of PUMP-1 expression in normal and carcinoma tissues using quantitative PCR with a n internal β-tubulin control. Figure 18B shows the ratio of mRNA expression of PUMP-1 compared to the internal control β-tubulin in 10 normal and 44 ovarian carcinomas. Figure 19 shows a comparison of PCR amplified products for the hepsin, SCCE, protease M, PUMP-1 and Cathepsin L genes . DETAILED DESCRIPTION OF THE INVENTION This invention identifies a hepsin protease on ovarian and other tumor cells which is characteristic of this type of cancer, and in various combinations with other proteases, is characteristic of individual tumor types. Such information can provide the basis for diagnostic tests (assays or immunohistochemistry), prognostic evaluation (depending on the display pattern) and therapeutic intervention utilizing either antibodies directed at the protease, antisense vehicles for downregulation or protease inhibitors bo th from established inhibition data and/or for the design of new drugs . Long-term treatment of tumor growth, invasion and metastasis has not succeeded with existing chemotherapeutic agents - most tumors become resistant to drugs after multiple cycles of chemotherapy. A primary object of the present invention is a method for detecting the presence of malignant hyperplasia in a tissue sample. It is an advantage of the present invention that it has as a particular object the detection of cancer in ovarian tissue. The cancer is detected by analyzing a biological sample for the presence of markers to proteases that are specific indicators of certain types of cancer cells. This object may be accomplished by isolating mRNA from a sample or by detection of proteins by polyclonal o r preferably monoclonal antibodies. When using mRNA detection, th e method may be carried out by combining the isolated mRNA with reagents to convert to cDNA according to standard methods ; treating the converted cDNA with amplification reaction reagents (such as cDNA PCR reaction reagents) in a container along with a n appropriate mixture of nucleic acid primers selected from the list in Table 2 or as detailed above; reacting the contents of the container to produce amplification products; and analyzing the amplification products to detect the presence of malignant hyperplasia markers in the sample. For mRNA, the analyzing step may be accomplished using Northern Blot analysis to detect the presence of malignant hyperplasia markers in the amplification product. Northern Blot analysis is known in the art. The analysis step may be further accomplished by quantitatively detecting the presence of malignant hyperplasia marker in the amplification produce, and comparing th e quantity of marker detected against a panel of expected values for known presence or absence in normal and malignant tissue derived using similar primers. Another embodiment of the present invention are various nucleic acid sequences that are useful in the methods disclosed herein. These nucleic acid sequences are listed in Table 2. It is anticipated that these nucleic acid sequences be used in mixtures to accomplish the utility of this invention. Features o f such mixtures include: SEQ ID No. 1 with SEQ ID No. 2; SEQ LD No. 1 with SEQ ID No. 3; SEQ LD No. 4 with SEQ ID No. 5; SEQ ID No. 6 with SEQ ID No. 7; SEQ ID No. 8 with SEQ ID No. 9; and SEQ ID No. 10 with SEQ ID No. 11. The skilled artisan may be able to develop other nucleic acid sequences and mixtures thereof to accomplish th e benefit of this invention, but it is advantageous to have th e sequences listed in Table 2 available without undue experimentation. The present invention is directed toward a method o f diagnosing cancer in an individual, comprising the steps of obtaining a biological sample from an individual; and detecting hepsin in the sample. The presence of hepsin in the sample is indicative of the presence of cancer in the individual, wherein the absence of hepsin in the sample is indicative of the absence of cancer in the individual. Generally, detection of the hepsin is by means such as Northern blot, Western blot, PCR, dot blot, ELISA sandwich assay, radioimmunoassay, DNA array chips and flow cytometry. An example of a typical cancer diagnosed by this method is ovarian cancer. The present invention is also directed toward a method for detecting malignant hyperplasia in a biological sample, comprising the steps of isolating mRNA from the sample; and detecting hepsin mRNA in the sample. The presence of the hepsin mRNA in the sample is indicative of the presence of malignant hyperplasia, wherein the absense of the hepsin mRNA in the sample is indicative of the absence of malignant hyperplasia. This method may further comprise the step of comparing the hepsin mRNA t o reference information, wherein the comparison provides a diagnosis and/or determines a treatment of the malignant hyperplasia. A typical means of detection of hepsin mRNA is by PCR amplification, which, preferably, uses primers shown in SEQ ID No. 8 and SEQ ID No. 9. Representative biological samples include a tissue and a bodily fluid, wherein the bodily fluid is preferably blood. The present invention is additionally directed toward a method for detecting malignant hyperplasia in a biological sample, comprising the steps of isolating protein from the sample; an d detecting hepsin protein in the sample. The presence of the hepsin protein in the sample is indicative of the presence of malignant hyperplasia, wherein the absense of the hepsin protein in the sample is indicative of the absence of malignant hyperplasia. This method also may comprise the step of comparing the hepsin protein t o reference information, wherein the comparison provides a diagnosis or determines a treatment of the malignant hyperplasia. Preferably, the detection of the hepsin protein is by immunoaffinity to a n antibody which is specific for hepsin. Representative biological samples are a tissue and a bodily fluid, and it is preferable that th e bodily fluid is blood. The present invention is further directed toward a method of inhibiting expression of hepsin in a cell, comprising the step of introducing a vector into a cell, wherein the vector comprises a hepsin gene in opposite orientation operably linked t o elements necessary for expression, wherein expression of the vector produces hepsin antisense mRNA in the cell. The hepsin antisense mRNA hybridizes to endogenous hepsin mRNA, thereby inhibiting expression of hepsin in the cell. The present invention is still further directed toward a method of inhibiting a hepsin protein in a cell, comprising the step of introducing an antibody into a cell, wherein the antibody is specific for a hepsin protein or a fragment thereof. Binding of th e antibody to hepsin inhibits the hepsin protein. Preferably, th e hepsin fragment is a 9-residue fragment up to a 20-residue fragment, and more preferably, the 9-residue fragment is SEQ ID Nos. 28, 29, 30, 31, 88, 89, 108, 109, 128, 129, 148, 149, 150, 1 5 1 , 152, 153 and 154. The present invention is also directed toward a method of targeted therapy to an individual, comprising the step o f administering a compound to an individual, wherein the comp ound has a targeting moiety and a therapeutic moiety, and wherein th e targeting moiety is specific for hepsin. Preferably, the targeting moiety is an antibody specific for hepsin or a ligand or ligand binding domain that binds hepsin. Likewise, the therapeutic moiety is preferably a radioisotope, a toxin, a chemotherapeutic agent, a n immune stimulant or cytotoxic agent. Generally, the individual suffers from a disease such as ovarian cancer, lung cancer, prostate cancer, colon cancer or another cancer in which hepsin is overexpressed. The present invention is additionally directed toward a method of vaccinating an individual against hepsin, comprising th e steps of inoculating an individual with a hepsin protein or fragment thereof, wherein the hepsin protein or fragment thereof lack hepsin protease activity. Inoculation with the hepsin protein, or fragment thereof, elicits an immune response in the individual, thereby vaccinating the individual against hepsin. Generally, this method is applicable when the individual has cancer, is suspected of having cancer or is at risk of getting cancer. Sequences of preferred hepsin proteins or fragment thereof are shown in SEQ ID Nos. 28, 29, 30 , 31, 88, 89, 108, 109, 128, 129, 148, 149, 150, 151 , 152, 153 an d 154. The present invention is yet directed toward a method of producing immune-activated cells directed toward hepsin, comprising the steps of exposing dendritic cells to hepsin protein o r fragment thereof, which lacks hepsin protease activity. Typically, exposure to hepsin protein or fragment thereof activates the dendritic cells, thereby producing immune-activated cells directed toward hepsin. Generally, the immune-activated cells are B-cells, T- cells and/or dendrites. Preferably, the hepsin fragment is a 9 - residue fragment up to a 20-residue fragment, and more preferably, the 9-residue fragment is SEQ ID Nos. 28, 29, 30, 31 , 88, 89, 108 , 109, 128, 129, 148, 149, 150, 151 , 152, 153 or 154. Oftentimes, the dendritic cells are isolated from an individual prior to exposure and then reintroduced into the individual subsequent to the exposure. Typically, the individual has cancer, is suspected o f having cancer or is at risk of getting cancer. The present invention is further directed toward a n immunogenic composition, comprising an immunogenic fragment o f hepsin protein and an appropriate adjuvant. Preferably, th e fragment is a 9-residue fragment up to a 20-residue fragment, and more preferably, the 9-residue fragment is SEQ ID Nos. 28, 29, 30 , 31, 88, 89, 108, 109, 128, 129, 148, 149, 150, 151, 152, 153 o r 154. The present invention is further directed toward a n oligonucleotide having a sequence complementary to SEQ ID No. 188 or a frgament thereof. The present invention further provides a composition comprising the above-described oligonucleotide and a physiologically acceptable carrier therefore, and a method o f treating a neoplastic state in an individual in need of such treatment, comprising the step of administering to the individual a n effective dose of the above-described oligonucleotide. Typically, th e neoplastic state may be ovarian cancer, breast cancer, lung cancer, colon cancer, prostate cancer or another cancer in which hepsin is overexpressed. The present invention is still further directed toward a method of screening for compounds that inhibit hepsin activity, comprising the steps of contacting a sample with a compound, wherein the sample comprises . hepsin protein; and assaying for hepsin protease activity. A decrease in the hepsin protease activity in the presence of the compound relative to hepsin protease activity in the absence of the compound is indicative of a compound th at inhibits hepsin activity. The present invention is yet additionally directed toward a method for detecting ovarian malignant hyperplasia in a biological sample, comprising the steps of isolating the proteases or protease mRNA present in the biological sample; and detecting specific proteases or protease mRNA present in the biological sample. The proteases are selected from the group consisting of hepsin, protease M, complement factor B, SCCE, cathepsin L and PUMP-1. This method may further comprise the step of comparing the specific proteases or protease mRNA detected to reference information, wherein the comparison provides a diagnoses or determines a treatment of the malignant hyperplasia. Typically, the protease mRNA is detected by amplification of total mRNA, and the protease is detected with an antibody. Representative biological samples are blood, urine, saliva, tears, interstitial fluid, ascites fluid, tumor tissue biopsy and circulating tumor cells. It will be apparent to one skilled in the art that various substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of th e invention. In accordance with the present invention there may b e employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Maniatis, Fritsch & Sambrook, "Molecular Cloning: A Laboratory Manual (1982); "DNA Cloning: A Practical Approach," Volumes I and II (D.N. Glover ed. 1985); "Oligonucleotide Synthesis" (M.J. Gait ed. 1984 ) ; "Nucleic Acid Hybridization" (B.D. Hames & S.J. Higgins eds. 1985 ) ; "Transcription and Translation" (B.D. Hames & S.J. Higgins eds . 1984); "Animal Cell Culture" (R.I. Freshney, ed. 1986); "Immobilized Cells And Enzymes" (IRL Press, 1986); B. Perbal, "A Practical Guide To Molecular Cloning" (1984). Therefore, if appearing herein, the following terms shall have the definitions set out below. As used herein, the term "cDNA" shall refer to the DNA copy of the mRNA transcript of a gene. As used herein, the term "derived amino acid sequence" shall mean the amino acid sequence determined by reading th e triplet sequence of nucleotide bases in the cDNA. As used herein the term "screening a library" shall refer to the process of using a labeled probe to check whether, under th e appropriate conditions, there is a sequence complementary to th e probe present in a particular DNA library. In addition, "screening a library" could be performed by PCR. As used herein, the term "PCR" refers to the polymerase chain reaction that is the subject of U.S. Patent Nos. 4,683, 195 an d 4,683,202 to Mullis, as well as other improvements now known in the art. The amino acid described herein are preferred to be in the "L" isomeric form. However, residues in the "D" isomeric form can be substituted for any L-amino acid residue, as long as th e desired functional property of immunoglobulin-binding is retained by the polypeptide. NH 2 refers to the free amino group present a t the amino terminus of a polypeptide. COOH refers to the free carboxy group present at the carboxy terminus of a polypeptide. In keeping with standard polypeptide nomenclature, J Biol. Chem. , 243:3552-59 (1969), abbreviations for amino acid residues may b e u sed . It should be noted that all amino-acid residue sequences are represented herein by formulae whose left and right orientation is in the conventional direction of amino-terminus to carboxy- terminus. Furthermore, it should be noted that a dash at th e beginning or end of an amino acid residue sequence indicates a peptide bond to a further sequence of one or more amino-acid residues . A "replicon" is any genetic element (e.g., plasmid, chromosome, virus) that functions as an autonomous unit of DNA replication in vivo; i. e., capable of replication under its own control. A "vector" is a replicon, such as plasmid, phage o r cosmid, to which another DNA segment may be attached so as t o bring about the replication of the attached segment. A "vector" may further be defined as a replicable nucleic acid construct, e.g., a plasmid or viral nucleic acid. A "DNA molecule" refers to the polymeric form o f deoxyribonucleotides (adenine, guanine, thymine, or cytosine) in its either single-stranded form or as a double-stranded helix. This term refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes double-stranded DNA found, inter alia, in linear DNA molecules (e. g., restriction fragments), viruses, plasmids, and chromosomes. The structure is discussed herein according to th e normal convention of giving only the sequence in the 5' to 3 ' direction along the nontranscribed strand of DNA (i. e., the strand having a sequence homologous to the mRNA). An expression vector is a replicable construct in which a nucleic acid sequence encoding a polypeptide is operably linked t o suitable control sequences capable of effecting expression of th e polypeptide in a cell. The need for such control sequences will vary depending upon the cell selected and the transformation method chosen. Generally, control sequences include a transcriptional promoter and/or enhancer, suitable mRNA ribosomal binding sites and sequences which control the termination of transcription and translation. Methods which are well known to those skilled in th e art can be used to construct expression vectors containing appropriate transcriptional and translational control signals. See, for example, techniques described in Sambrook et al., 1989 , Molecular Cloning: A Laboratory Manual (2nd Ed.), Cold Spring Harbor Press, N.Y. A gene and its transcription control sequences are defined as being "operably linked" if the transcription control sequences effectively control transcription of the gene. Vectors o f the invention include, but are not limited to, plasmid vectors and viral vectors. Preferred viral vectors of the invention are tho se derived from retroviruses, adenovirus, adeno-associated virus, SV40 virus, or herpes viruses. In general, expression vectors contain promoter sequences which facilitate the efficient transcription o f the inserted DNA fragment and are used in connection with a specific host. The expression vector typically contains an origin o f replication, promoter(s), terminator(s), as well as specific genes which are capable of providing phenotypic selection in transformed cells. The transformed hosts can be fermented and cultured according to means known in the art to achieve optimal cell growth. An "origin of replication" refers to those DNA sequences that participate in DNA synthesis. A DNA "coding sequence" is a double-stranded DNA sequence which is transcribed and translated into a polypeptide in vivo when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are typically determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxyl) terminus. A coding sequence can include, but is not limited to, prokaryotic sequences , cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic (e.g., mammalian) DNA, and even synthetic DNA sequences. A polyadenylation signal and transcription termination sequence will usually be located 3' to the coding sequence. Transcriptional and translational control sequences are DNA regulatory sequences, such as promoters, enhancers, polyadenylation signals, terminators, and the like, that provide for the expression of a coding sequence in a host cell. A "promoter sequence" is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence. For purposes of defining the present invention, the promoter sequence is bounded at its 3' terminus by the transcription initiation site and extends upstream (5' direction) to include the minimum number o f bases or elements necessary to initiate transcription at levels detectable above background. Within the promoter sequence will be found a transcription initiation site, as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase. Eukaryotic promoters often, but not always, contain "TATA" boxes and "CAT" boxes. Prokaryotic promoters typically contain Shine-Dalgarno ribosome-binding sequences in addition t o the - 10 and -35 consensus sequences. An "expression control sequence" is a DNA sequence th at controls and regulates the transcription and translation of another DNA sequence. A coding sequence is "under the control" of transcriptional and translational control sequences in a cell when RNA polymerase transcribes the coding sequence into mRNA, which is then translated into the protein encoded by the coding sequence. A "signal sequence" can be included near the coding sequence. This sequence encodes a signal peptide, N-terminal to th e polypeptide, that communicates to the host cell to direct th e polypeptide to the cell surface or secrete the polypeptide into th e media, and this signal peptide is clipped off by the host cell before the protein leaves the cell. Signal sequences can be found associated with a variety of proteins native to prokaryotes and eukaryotes . As used herein, the terms "restriction endonucleases" and "restriction enzymes" refer to enzymes, each of which c u t double-stranded DNA at or near a specific nucleotide sequence. A cell has been "transformed" by exogenous o r heterologous DNA when such DNA has been introduced inside th e cell. The transforming DNA may or may not be integrated (covalently linked) into the genome of the cell. In prokaryotes , yeast, and mammalian cells for example, the transforming DNA may be maintained on an episomal element such as a plasmid. With respect to eukaryotic cells, a stably transformed cell is one in which the transforming DNA has become integrated into a chromosome s o that it is inherited by daughter cells through chromo some replication. This stability is demonstrated by the ability of the eukaryotic cell to establish cell lines or clones comprised of a population of daughter cells containing the transforming DNA. A "clone" is a population of cells derived from a single cell or ancestor by mitosis. A "cell line" is a clone of a primary cell that is capable of stable growth in vitro for many generations. Two DNA sequences are "substantially homologous " when at least about 75% (preferably at least about 80%, and mo s t preferably at least about 90% or 95%) of the nucleotides match over the defined length of the DNA sequences. Sequences that are substantially homologous can be identified by comparing th e sequences using standard software available in sequence data banks , or in a Southern hybridization experiment under, for example, stringent conditions as defined for that particular system. Defining appropriate hybridization conditions is within the skill of the art. See, e.g., Maniatis et al., supra; DNA Cloning, Vols. I & II, supra; Nucleic Acid Hybridization, supra. A "heterologous" region of the DNA construct is a n identifiable segment of DNA within a larger DNA molecule that is no t found in association with the larger molecule in nature. Thus, when the heterologous region encodes a mammalian gene, the gene will usually be flanked by DNA that does not flank the mammalian genomic DNA in the genome of the source organism. Another example is a construct where the coding sequence itself is not found in nature (e.g., a cDNA where the genomic coding sequence contains introns, or synthetic sequences having codons different than the native gene). Allelic variations or naturally-occurring mutational events do not give rise to a heterologous region of DNA as defined herein . The labels most commonly employed for these studies are radioactive elements, enzymes, chemicals which fluoresce when exposed to ultraviolet light, and others. A number of fluorescent materials are known and can be utilized as labels. These include, for example, fluorescein, rhodamine, auramine, Texas Red, AMCA blue and Lucifer Yellow. A particular detecting material is anti- rabbit antibody prepared in goats and conjugated with fluorescein through an isothiocyanate. Proteins can also be labeled with a radioactive element or with an enzyme. The radioactive label can b e detected by any of the currently available counting procedures. The preferred isotope may be selected from 3 H, 14 C, 32 P, 35 S, 36 C1, 51 Cr, 57 Co, 58 Co, 59 Fe, 90 Y, 125 I, 131 I, and 186 Re. Enzyme labels are likewise useful, and can be detected by any of the presently utilized colorimetric, spectrophotometric, fluorospectrophotometric, amperometric or gasometric techniques. The enzyme is conjugated to the selected particle by reaction with bridging molecules such a s carbodiimides, diisocyanates, glutaraldehyde and the like. Many enzymes which can be used in these procedures are known and c an be utilized. The preferred are peroxidase, β-glucuronidase, β-D- glucosidase, β-D-galactosidase, urease, glucose oxidase plus peroxidase and alkaline phosphatase. U.S. Patent Nos. 3 ,654 ,090, 3,850,752, and 4,016,043 are referred to by way of example for their disclosure of alternate labeling material and methods. A particular assay system developed and utilized in the art is known as a receptor assay. In a receptor assay, the material t o be assayed is appropriately labeled and then certain cellular test colonies are inoculated with a quantitiy of both the label after which binding studies are conducted to determine the extent to which th e labeled material binds to the cell receptors. In this way, differences in affinity between materials can be ascertained. An assay useful in the art is known as a "cis/trans" assay. Briefly, this assay employs two genetic constructs, one of which is typically a plasmid that continually expresses a particular receptor of interest when transfected into an appropriate cell line, and the second of which is a plasmid that expresses a reporter such a s luciferase, under the control of a receptor/ligand complex. Thus, for example, if it is desired to evaluate a compound as a ligand for a particular receptor, one of the plasmids would be a construct th at results in expression of the receptor in the chosen cell line, while the second plasmid would possess a promoter linked to th e luciferase gene in which the response element to the particular receptor is inserted. If the compound under test is an agonist for the receptor, the ligand will complex with the receptor, and th e resulting complex will bind the response element and initiate transcription of the luciferase gene. The resulting chemiluminescence is then measured photometrically, and do se response curves are obtained and compared to those of known ligands. The foregoing protocol is described in detail in U.S. Patent No. 4,981 ,784. As used herein, the term "host" is meant to include no t only prokaryotes but also eukaryotes such as yeast, plant and animal cells. A recombinant DNA molecule or gene which encodes a human hepsin protein of the present invention can be used t o transform a host using any of the techniques commonly known t o those of ordinary skill in the art. Especially preferred is the use of a vector containing coding sequences for the gene which encodes a human hepsin protein of the present invention for purposes o f prokaryote transformation. Prokaryotic hosts may include E. coli, S. tymph imurium, Serratia marcescens and Bacillus subtilis. Eukaryotic hosts include yeasts such as Pichia pastoris, mammalian cells and insect cells. As used herein, "substantially pure DNA" means DNA that is not part of a milieu in which the DNA naturally occurs, b y virtue of separation (partial or total purification) of some or all o f the molecules of that milieu, or by virtue of alteration of sequences that flank the claimed DNA. The term therefore includes, for example, a recombinant DNA which is incorporated into a vector, into an autonomously replicating plasmid or virus, or into th e genomic DNA of a prokaryote or eukaryote; or which exists as a separate molecule (e. g., a cDNA or a genomic or cDNA fragment produced by polymerase chain reaction (PCR) or restriction endonuclease digestion) independent of other sequences. It also includes a recombinant DNA which is part of a hybrid gene encoding additional polypeptide sequence, e.g., a fusion protein. Also included is a recombinant DNA which includes a portion of th e nucleotides listed in SEQ ID No. 188 and which encodes a n alternative splice variant of hepsin. By a "substantially pure protein" is meant a protein which has been separated from at least some of those components which naturally accompany it. Typically, the protein is substantially pure when it is at least 60% (by weight) free from the proteins and other naturally-occurring organic molecules with which it is naturally associated in vivo . Preferably, the purity of the preparation (by weight) is at least 75%, more preferably at least 90%, and most preferably at least 99%. A substantially pure hepsin protein may be obtained, for example, by extraction from a natural source; by expression of a recombinant nucleic acid encoding a hepsin polypeptide; or by chemically synthesizing the protein. Purity can be measured by any appropriate method, e.g., column chromatography, such as immunoaffinity chromatography using a n antibody specific for hepsin, polyacrylamide gel electrophoresis, o r HPLC analysis. A protein is substantially free of naturally associated components when it is separated from at least some of those contaminants which accompany it in its natural state. Thus, a protein which is chemically synthesized or produced in a cellular system different from the cell from which it naturally originates will be, by definition, substantially free from its naturally associated components. Accordingly, substantially pure proteins include eukaryotic proteins synthesized in E. coli, other prokaryotes, or any other organism in which they do not naturally occur. The term "oligonucleotide", as used herein, is defined a s a molecule comprised of two or more ribonucleotides, preferably more than three. Its exact size will depend upon many factors, which, in turn, depend upon the ultimate function and use of th e oligonucleotide. The term "primer", as used herein, refers to a n oligonucleotide, whether occurring naturally (as in a purified restriction digest) or produced synthetically, and which is capable of initiating synthesis of a strand complementary to a nucleic acid when placed under appropriate conditions, i. e., in the presence o f nucleotides and an inducing agent, such as a DNA polymerase, and at a suitable temperature and pH. The primer may be either single- stranded or double-stranded and must be sufficiently long to prime the synthesis of the desired extension product in the presence of th e inducing agent. The exact length of the primer will depend up on many factors, including temperature, sequence and/or homology o f primer and the method used. For example, in diagnostic applications, the oligonucleotide primer typically contains 15-25 o r more nucleotides, depending upon the complexity of the target sequence, although it may contain fewer nucleotides. The primers herein are selected to be "substantially" complementary to particular target DNA sequences. This means that the primers must be sufficiently complementary to hybridize with their respective strands. Therefore, the primer sequence need not reflect the exact sequence of the template. For example, a non- complementary nucleotide fragment (i. e., containing a restriction site) may be attached to the 5' end of the primer, with th e remainder of the primer sequence being complementary to th e strand. Alternatively, non-complementary bases or longer sequences can be interspersed into the primer, provided that th e primer sequence has sufficient complementary with the sequence t o hybridize therewith and form the template for synthesis of the extension product. The probe to which the DNA of the invention hybridizes preferably consists of a sequence of at least 20 consecutive nucleotides, more preferably 40 nucleotides, even more preferably 50 nucleotides, and most preferably 100 nucleotides or more (up t o 100%) of the coding sequence of the nucleotides listed in SEQ ID No. 188 or the complement thereof. Such a probe is useful for detecting expression of hepsin in a cell by a method including th e steps of (a) contacting mRNA obtained from the cell with a labeled hepsin hybridization probe; and (b) detecting hybridization of th e probe with the mRNA. By "high stringency" is meant DNA hybridization and wash conditions characterized by high temperature and low salt concentration, e.g., wash conditions of 65°C at a salt concentration of approximately 0.1X SSC, or the functional equivalent thereof. For example, high stringency conditions may include hybridization a t about 42°C in the presence of about 50% formamide; a first wash a t about 65°C with about 2X SSC containing 1% SDS; followed by a second wash at about 65°C with about 0.1X SSC. The DNA may have at least about 70% sequence identity to the coding sequence of the nucleotides listed in SEQ ID No. 1 88 , preferably at least 75% (e.g., at least 80%); and most preferably a t least 90%. The identity between two sequences is a direct function of the number of matching or identical positions. When a position in both of the two sequences is occupied by the same monomeric subunit, e.g., if a given position is occupied by an adenine in each o f two DNA molecules, then they are identical at that position. For example, if 7 positions in a sequence 10 nucleotides in length are identical to the corresponding positions in a second 10-nucleotide sequence, then the two sequences have 70% sequence identity. The length of comparison sequences will generally be at least 50 nucleotides, preferably at least 60 nucleotides, more preferably at least 75 nucleotides, and most preferably 100 nucleotides . Sequence identity is typically measured using sequence analysis software (e.g., Sequence Analysis Software Package of the Genetics Computer Group (GCG), University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, WI 53705). The present invention comprises a vector comprising a DNA sequence which encodes a hepsin protein, wherein said vector is capable of replication in a host, and comprises, in operable linkage: a) an origin of replication; b) a promoter; and c) a DNA sequence coding for said hepsin protein. Preferably, the vector o f the present invention contains a portion of the DNA sequence shown in SEQ ID No. 188. Vectors may be used to amplify and/or express nucleic acid encoding a hepsin protein or fragment thereof. In addition to substantially full-length proteins, th e invention also includes fragments (e.g., antigenic fragments) of th e hepsin protein. As used herein, "fragment," as applied to a polypeptide, will ordinarily be at least 10 residues, more typically a t least 20 residues, and preferably at least 30 (e.g., 50) residues in length, but less than the entire, intact sequence. Fragments of th e hepsin protein can be generated by methods known to those skilled in the art, e.g., by enzymatic digestion of naturally occurring o r recombinant hepsin protein, by recombinant DNA techniques using an expression vector that encodes a defined fragment of hepsin, o r by chemical synthesis. The ability of a candidate fragment to exhibit a characteristic of hepsin (e.g., binding to an antibody specific for hepsin) can be assessed by methods described herein. Purified hepsin or antigenic fragments of hepsin can be used to generate new antibodies or to test existing antibodies (e.g., as positive controls in a diagnostic assay) by employing standard protocols known to tho se skilled in the art. Included in this invention is polyclonal anti sera generated by using hepsin or a fragment of hepsin as th e immunogen in, e.g., rabbits. Standard protocols for monoclonal and polyclonal antibody production known to those skilled in this ar t are employed. The monoclonal antibodies generated by this procedure can be screened for the ability to identify recombinant hepsin cDNA clones, and to distinguish them from other cDNA clones . Further included in this invention are hepsin proteins which are encoded, at least in part, by portions of SEQ ID No. 1 88 , e.g., products of alternative mRNA splicing or alternative protein processing events, or in which a section of hepsin sequence has been deleted. The fragment, or the intact hepsin polypeptide, may be covalently linked to another polypeptide, e.g., one which acts a s a label, a ligand or a means to increase antigenicity. The invention also includes a polyclonal or monoclonal antibody which specifically binds to hepsin. The invention encompasses not only an intact monoclonal antibody, but also a n immunologically-active antibody fragment, e.g., a Fab or (Fab) 2 fragment; an engineered single chain Fv molecule; or a chimeric molecule, e.g., an antibody which contains the binding specificity o f one antibody, e.g., of murine origin, and the remaining portions o f another antibody, e.g., of human origin. In one embodiment, the antibody, or a fragment thereof, may be linked to a toxin or to a detectable label, e.g., a radioactive label, non-radioactive isotopic label, fluorescent label, chemiluminescent label, paramagnetic label, enzyme label, o r colorimetric label. Examples of suitable toxins include diphtheria toxin, Pseudomonas exotoxin A, ricin, and cholera toxin. Examples of suitable enzyme labels include malate hydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, alcohol dehydrogenase, alpha-glycerol phosphate dehydrogenase, triose phosphate isomerase, peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase, acetylcholinesterase, etc. Examples of suitable radioisotopic labels include 3 H, , 25 I, 131 I, 2 P, 35 S, 14 C, etc. Paramagnetic isotopes for purposes of in vivo diagnosis can also be used according to the methods of this invention. There are numerous examples of elements that are useful in magnetic resonance imaging. For discussions on in vivo nuclear magnetic resonance imaging, see, for example, Schaefer et al., (1989) JACC 14, 472-480; Shreve et al., (1986) Magn. Reson. Med. 3, 336-340 ; Wolf, G. L., (1984) Physiol. Chem. Phys. Med. NMR 16, 93 -95 ; Wesbey et al., ( 1984) Physiol. Chem. Phys. Med. NMR 16, 145 - 155 ; Runge et al., ( 1984) Invest. Radiol. 19, 408-415. Examples o f suitable fluorescent labels include a fluorescein label, a n isothiocyalate label, a rhodamine label, a phycoerythrin label, a phycocyanin label, an allophycocyanin label, an ophthaldehyde label, a fluorescamine label, etc. Examples of chemiluminescent labels include a luminal label, an isoluminal label, an aromatic acridinium ester label, an imidazole label, an acridinium salt label, an oxalate ester label, a luciferin label, a luciferase label, a n aequorin label, etc. Those of ordinary skill in the art will know of other suitable labels which may be employed in accordance with th e present invention. The binding of these labels to antibodies o r fragments thereof can be accomplished using standard techniques commonly known and used by those of ordinary skill in the art . Typical techniques are described by Kennedy et al., (1976) Clin. Chim. Acta 70, 1-31 ; and Schurs et al., ( 1977) Clin. Chim. Acta 8 1 , 1-40. Coupling techniques mentioned in the latter are th e glutaraldehyde method, the periodate method, the dimaleimide method, the m-maleimidobenzyl-N-hydroxy-succinimide ester method. All of these methods are incorporated by reference herein. Also within the invention is a method of detecting hepsin protein in a biological sample, which includes the steps o f contacting the sample with the labeled antibody, e.g., radioactively tagged antibody specific for hepsin, and determining whether th e antibody binds to a component of the sample. Antibodies to th e hepsin protein can be used in an immunoassay to detect increased levels of hepsin protein expression in tissues suspected of neoplastic transformation. These same uses can be achieved with Northern blot assays and analyses. As described herein, the invention provides a number o f diagnostic advantages and uses. For example, the hepsin protein is useful in diagnosing cancer in different tissues since this protein is highly overexpressed in tumor cells. Antibodies (or antigen-binding fragments thereof) which bind to an epitope specific for hepsin are useful in a method of detecting hepsin protein in a biological sample for diagnosis of cancerous or neoplastic transformation. This method includes the steps of obtaining a biological sample (e. g. , cells, blood, plasma, tissue, etc.) from a patient suspected of having cancer, contacting the sample with a labeled antibody (e. g. , radioactively tagged antibody) specific for hepsin, and detecting th e hepsin protein using standard immunoassay techniques such as a n ELISA. Antibody binding to the biological sample indicates that the sample contains a component which specifically binds to an epitope within hepsin. Likewise, a standard Northern blot assay can be used t o ascertain the relative amounts of hepsin mRNA in a cell or tissue obtained from a patient suspected of having cancer, in accordance with conventional Northern hybridization techniques known t o those of ordinary skill in the art. This Northern assay uses a hybridization probe, e.g., radiolabelled hepsin cDNA, either containing the full-length, single stranded DNA having a sequence complementary to SEQ ID No. 188, or a fragment of that DNA sequence at least 20 (preferably at least 30, more preferably at least 50, and most preferably at least 100 consecutive nucleotides in length). The DNA hybridization probe can be labeled by any of th e many different methods known to those skilled in this art. The following examples are given for the purpose o f illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion: EXAMPLE 1 Amplification of serine proteases using redundant and specifi c pri m ers Only cDNA preparations deemed free of genomic DNA were used for gene expression analysis. Redundant primers were prepared for serine proteases, metallo-proteases and cysteine protease. The primers were synthesized to consensus sequences o f amino acid surrounding the catalytic triad for serine proteases, viz. histidine ... aspartate ... and serine. The sequences of both sense (histidine & aspartate) and antisense (aspartate and serine) redundant primers are shown in Table 2. TABLE 2 PCR Primers .v→r SF.Q TD No. Redundant Primers: Serine Protease (histidine) = S I tgggtigtiacigcigcica(ct)tg 1 Serine Protease (aspartic acid) = AS l a(ag)ia(ag)igciatitcitticc 2 Serine Protease (serine) = AS H a(ag)iggiccicci(cg)(ta)(ag)tcicc 3 Cysteine Protease - sense ca(ag)ggica(ag)tg(ct)ggi(ta)(cg)itg(ct)tgg 4 Cysteine Protease - antisense taiccicc(ag)tt(ag)caicc(ct)tc 5 Metallo Protease - sense cci(ac)gitg(tc)ggi(ga)(ta)icciga 6 Metallo Protease - antisense tt(ag)tgicciai(ct)tc(ag)tg 7 Specific Primers: Serine Protease (hepsin) = sense tgtcccgatggcgagtgttt 8 Serine Protease (hepsin) = antisense cctgttggccatagtactgc 9 Serine Protease (SCCE) = sense agatgaatgagtacaccgtg 10 Serine Protease (SCCE) = antisense ccagtaagtccttgtaaacc 11 Serine Protease (Comp B) = sense aagggacacgagagctgtat 12 Serine Protease (Comp B) = antisense aagtggtagttggaggaagc 13 Serine Protease (Protease M)= sense ctgtgatccaccctgactat 20 Serine Protease (Protease M) = antisense caggtggatgtatgcacact 21 Serine Protease (TADG12) = sense (SerlO-s) gcgcactgtgtttatgagat 22 Serine Protease (TADG12) = antisense (SerlO-as) ctctttggcttgtacttgct 23 Serine Protease (TADG13) = sense tgagggacatcattatgcac 24 Serine Protease (TADG13) = antisense caagttttccccataattgg 25 Serine Protease (TADG14) = sense acagtacgcctgggagacca 26 Serine Protease (TADG14) = antisense ctgagacggtgcaattctgg 27 Cysteine Protease (Cath-L) = sense attggagagagaaaggctac 14 Cysteine Protease (Cath-L) = antisense cttgggattgtacttacagg 15 Metallo Protease (PUMP1) = sense cttccaaagtggtcacctac 16 Metallo Protease (PUMP1) = antisense ctagactgctaccatccgtc 17 FXAMPT.F 2 Carcinoma ti sue Several protease entities were identified and subcloned from PCR amplification of cDNA derived from serou s cystadenocarcinomas. Therefore, the proteases described herein are reflective of surface activities for this type of carcinoma, th e most common form of ovarian cancer. Applicant has also shown PCR amplification bands unique to the mucinous tumor type and th e clear cell type of similar base pair size. About 20-25% of ovarian cancers are classified as either mucinous, clear cell, o r endometrioid . EXAMPLE 3 Ligation, tran formati n and sequencing To determine the identity of the PCR products, all th e appropriate bands were ligated into Promega T- vector plasmid an d the ligation product was used to transform JM109 cells (Promega) grown on selective media. After selection and culturing o f individual colonies, plasmid DNA was isolated by means of th e WIZARD MLNIPREP™ DNA purification system (Promega). Inserts were sequenced using a Prism Ready Reaction Dydeoxy Terminators cycle sequencing kit (Applied Biosystems). Residual dye terminators were removed from the completed sequencing reaction using a ■CENTRISEP SPIN™ column (Princeton Separation), and samples were loaded into an Applied Biosystems Model 373A DNA sequencing system. The results of subcloning and sequencing for the serine protease primers are summarized in Table 3. TABLE 3 Serine protease candidates Snbcl one Primer Set Gene. Candidate 1 His-Ser Hepsin 2 His-Ser SCCE 3 His-Ser Compliment B 4 His-Asp Cofactor 1 5 His-Asp TADG-12* 6 His-Ser TADG-13* 7 His-Ser TADG-14* 8 His-Ser Protease M 9 Hi s-Ser TADG-1 * indicates novel proteases EXAMPLE 4 Cloning an d ch ar acteri zati on Cloning and characterization of new gene candidates was undertaken to expand the panel representative of extracellular proteases specific for ovarian carcinoma subtypes. Sequencing o f the PCR products derived from tumor cDNA confirms the potential candidacy of these genes. The three novel genes all have conserved residues within the catalytic triad sequence consistent with their membership in the serine protease family. Applicant compared the PCR products amplified from normal and carcinoma cDNAs using sense-histidine and antisense- aspartate as well as sense-histidine and antisense-serine. The anticipated PCR products of approximately 200 bp and 500 bp for those pairs of primers were observed (aspartate is approximately 50-70 amino acids downstream from histidine, and serine is about 100-150 amino acids toward the carboxy end from histidine). Figure 1 shows a comparison of PCR products derived from normal and carcinoma cDNA as shown by staining in a n agarose gel. Two distinct bands in Lane 2 were present in the primer pair sense-His/antisense ASP (AS l) and multiple bands of about 500 bp are noted in the carcinoma lane for the sense-His/antisense-Ser (AS2) primer pairs in Lane 4. EXAMPLE 5 Quantitative PCR The mRNA overexpression of hepsin was detected and determined using quantitative PCR. Quantitative PCR was performed generally according to the method of Noonan et al. [Proc. Natl.Acad.ScL, USA, 87:7160-7164 (1990)] . The following oligonucleotide primers were used: hepsin: forward 5'-TGTCCCGATGGCGAGTGTTT-3' (SEQ ID No. 8), and reverse 5'-CCTGTTGGCCATAGTACTGC-3' (SEQ ID No. 9); and β-tubulin: forward 5'- TGCATTGACAACGAGGC -3' (SEQ ID No. 18), and reverse 5'- CTGTCTTGA CATTGTTG -3* (SEQ ID No. 19). β-tubulin was utilized as an internal control. The predicted sizes of the amplified genes were 282 bp for hepsin and 454 bp for β- tubulin. The primer sequences used in this study were designed according to the cDNA sequences described by Leytus et al. [Biochemistry, 27, 1067- 1074 (1988)] for hepsin, and Hall et al. [Mol. Cell. Biol, 3, 854-862 (1983)] for β-tubulin. The PCR reaction mixture consisted of cDNA derived from 50 ng of mRNA converted by conventional techniques, 5 pmol of sense and antisense primers for both the hepsin gene and the β-tubulin gene, 200 μmol of dNTPs, 5 μCi of α- 32 PdCTP and 0.25 units of Taq DNA polymerase with reaction buffer (Promega) in a final volume of 25 μl. The target sequences were amplified in parallel with the β-tubulin gene. Thirty cycles of PCR were carried out in a Thermal Cycler (Perkin-Elmer Cetus). Each cycle of PCR included 30 sec of denaturation at 95°C, 30 sec of annealing at 63°C and 30 sec of extension at 72°C. The PCR products were separated on 2% agarose gels and the radioactivity o f each PCR product was determined by using a Phosphorlmager™ (Molecular Dynamics). Student's t test was used for comparison of mean values. Experiments comparing PCR amplification in normal ovary and ovarian carcinoma suggested overexpression and/or alteration in mRNA transcript in tumor tissues. Northern blot analysis of TADG-14 confirms a transcript size of 1.4 kb and data indicate overexpression in ovarian carcinoma (Figure 2). Isolation and purification using both PCR and a specific 250 bp PCR product t o screen positive plaques yielded a 1.2 kb clone of TADG-14. Other proteases were amplified by the same method using the appropriate primers from Table 2. EXAMPLE 6 Tissue bank A tumor tissue bank of fresh frozen tissue of ovarian carcinomas as shown in Table 4 was used for evaluation. Approximately 100 normal ovaries removed for medical reasons other than malignancy were obtained from surgery and were available as controls. TABLE 4 Ovarian cancer tissue hank Total S are. T/11 -Slag e TTT/TV No Stage Serous Malignant 166 15 140 8 LMP 16 9 7 0 Benign 12 0 0 12 Mucinous Malignant 26 6 14 6 LMP 28 25 3 0 Benign 3 0 0 3 Endometrioid Malignant 38 17 21 0 LMP 2 2 0 0 Benign 0 0 0 0 Other* Malignant 61 23 29 9 LMP 0 0 0 0 nipn 5 0 0 5 *Other category includes the following tumor types: Brenner's tumor, thecoma, teratoma, fibrothecoma, fibroma, granulosa cell, clear cell, germ cell, mixed mullerian, stromal, undifferentiated, and dysgerminoma. From the tumor bank, approximately 100 carcinomas were evaluated encompassing most histological sub-types of ovarian carcinoma, including borderline or low-malignant potential tumors and overt carcinomas. The approach included using mRNA prepared from fresh frozen tissue (both normal and malignant) to comp are expression of genes in normal, low malignant potential tumors and overt carcinomas. The cDNA prepared from polyA + mRNA was deemed to be genomic DNA-free by checking all preparations with primers that encompassed a known intron-exon splice site using both β-tubulin and p53 primers. EXAMPLE 7 Northern blots Significant information can be obtained by examining th e expression of these candidate genes by Northern blot. Analysis of normal adult multi-tissue blots offers the opportunity to identify normal tissues which may express the protease. Ultimately, if strategies for inhibition of proteases for therapeutic intervention are to be developed, it is essential to appreciate the expression of these genes in normal tissue if and when it occurs. Significant information is expected from Northern blot analysis of fetal tissue. Genes overexpressed in carcinomas are often highly expressed in organogenesis. As indicated, the hepsin gene cloned from hepatoma cells and overexpressed in ovarian carcinoma is overtly expressed in fetal liver. Hepsin gene expression was also detected in fetal kidney, and therefore, could b e a candidate for expression in renal carcinomas. Northern panels for examining expression of genes in a multi-tissue normal adult as well as fetal tissue are commercially available (CLONTECH). Such evaluation tools are not only important to confirm the overexpression of individual transcripts in tumor versus normal tissues, but also provides the opportunity to confirm transcript size, and to determine if alternate splicing or other transcript alteration may occur in ovarian carcinoma. EXAMPLE S Northern blot analysis Northern blot analysis was performed as follows: 10 μg of mRNA was loaded onto a 1 % formaldehyde-agarose gel, electrophoresed and blotted onto a HyBond-N + ™ nylon membrane (Amersham). 32 P-labeled cDNA probes were made using Prime- a- Gene Labeling System™ (Promega). The PCR products amplified by specific primers were used as probes. Blots were prehybridized for 30 min and then hybridized for 60 min at 68°C with 32 P-labeled cDNA probe in ExpressHyb™ Hybridization Solution (CLONTECH). Control hybridization to determine relative gel loading was accomplished using the β-tubulin probe. Normal human tissues including spleen, thymus, prostate, testis, ovary, small intestine, colon, peripheral blood leukocyte, heart, brain, placenta, lung, liver, skeletal muscle, kidney, pancreas and normal human fetal tissues; brain, lung, liver and kidney (Human Multiple Tissue Northern Blot; CLONTECH) were all examined using the same hybridization procedure. EXAMPLE 9 PCR products corresponding tD serine, cysteine anrj metallo- proteases Based on their unique expression in either low malignant potential tumors or carcinomas, PCR-amplified cDNA products were cloned and sequenced and the appropriate gene identified based upon nucleotide and amino acid sequences stored in the GCG and EST databases. Figures 3, 4 & 5 show the PCR product displays comparing normal and carcinomatous tissues using redundant primers for serine proteases (Figure 3), for cysteine proteases (Figure 4) and for metallo-proteases (Figure 5). Note th e differential expression in the carcinoma tissues versus the normal tissues. The proteases were identified using redundant cDNA primers (see Table 2) directed towards conserved sequences that are associated with intrinsic enzyme activity (for serine proteases, cysteine proteases and metallo-proteases) by comparing mRNA expression in normal, low malignant potential and overt ovarian carcinoma tissues according to Sakanari et al. [Biochemistry 86, 4863-4867 (1989)] . EXAMPLE 10 Serine proteases For the serine protease group, using the histidine domain primer sense, SI, in combination with antisense primer AS2, the following proteases were identified: ( a) Hepsin, a trypsin-like serine protease cloned from hepatoma cells shown to be a cell surface protease essential for the growth of hepatoma cells in culture and highly expressed in hepatoma tumor cells (Figure 3, Lane 4); ( b ) Complement factor B protease (human factor IX), a protease involved in the coagulation cascade and associated with the production and accumulation of fibrin split products associated with tumor cells (Figure 3, Lane 4). Compliment factor B belongs in the family of coagulation factors X (Christmas factor). As part o f the intrinsic pathway, compliment factor B catalyzes the proteolytic activation of coagulation factor X in the presence of Ca 2+ phospholipid and factor Villa e5; and (c) A stratum corneum chymotryptic enzyme (SCCE) serine protease involved in desquarnation of skin cells from the human stratum corneum (Figure 3, Lane 4). SCCE is expressed in keratinocytes of the epidermis and functions to degrade the cohesive structures in the cornified layer to allow continuous skin surface shedding. EXAMPLE 11 Cysteine proteases In the cysteine protease group, using redundant sense and anti-sense primers for cysteine proteases, one unique PCR product was identified by overexpression in ovarian carcinoma when compared to normal ovarian tissue (Figure 4, Lanes 3 -5 ) . Cloning and sequencing this PCR product identified a sequence o f Cathepsin L, which is a lysomal cysteine protease whose expression and secretion is induced by malignant transformation, growth factors and tumor promoters. Many human tumors (including ovarian) express high levels of Cathepsin L. Cathepsin L cysteine protease belongs in the stromolysin family and has potent elastase and collagenase activities. Published data indicates increased levels in the serum of patients with mucinous cystadenocarcinoma of the ovary. It has not heretofore been shown to be expressed in other ovarian tumors. EXAMPLE 12 Using redundant sense and anti-sense primers for the metallo-protease group, one unique PCR product was detected in the tumor tissue which was absent in normal ovarian tissue (Figure 5 , Lanes 2-5). Subcloning and sequencing this product indicates it has complete homology in the appropriate region with the so-called PUMP-1 (MMP-7) gene. This zinc-binding metallo-protease is expressed as a proenzyme with a signal sequence and is active in gelatin and collagenase digestion. PUMP-1 has also been shown t o be induced and overexpressed in 9 of 10 colorectal carcinomas compared to normal colon tissue, suggesting a role for this substrate in the progression of this disease. EXAMPLE 13 Expression of hepsin The expression of the serine protease hepsin gene in 8 normal, 11 low malignant potential tumors, and 14 carcinoma (both mucinous and serous type) by quantitative PCR using hepsin-specific primers (see Table 2) was determined (primers directed toward the β-tubulin message were used as an internal standard) (Table 5 ) . These data confirm the overexpression of the hepsin surface protease gene in ovarian carcinoma, including both low malignant potential tumors and overt carcinoma. Expression of hepsin is increased over normal levels in low malignant potential tumors, and high stage tumors (Stage III) of this group have higher expression of hepsin when compared to low stage tumors (Stage 1) (Table 6). In overt carcinoma, serous tumors exhibit the highest levels of hepsin expression, while mucinous tumors express levels of hepsin comparable with the high stage low malignant potential group (Figures 6 & 7). TABLE 5 Patient Characteri tics and Expression of Hepsin Gene Case Histologies! type a Sta ge/Grade LNi mRNA expression of hepsin 0 1 1 nnoorrmmaall oovvaarryy n 2 normal ovary n 3 normal ovary n 4 normal ovary n 5 normal ovary n normal ovary n normal ovary n normal ovary n normal ovary n normal ovary n S adenoma (LMP) 1/1 N 4+ S adenoma (LMP) 1/1 NE 4+ S adenoma (LMP) 1/1 NE n S adenoma (LMP) 1/1 N 2+ S adenoma (LMP) 3/1 P 4+ S adenoma (LMP) 3/1 P 4+ S adenoma (LMP) 3/1 P 4+ M adenoma (LMP) 1/1 NE 4+ M adenoma (LMP) 1/1 N n M adenoma (LMP) 1/1 N n M adenoma (LMP) 1/1 N n M adenoma (LMP) 1/1 NE n S carcinoma 1/2 N 4+ S carcinoma 1/3 N 4+ s carcinoma 3/1 NE 2+ s carcinoma 3/2 NE 4+ s carcinoma 3/2 P 4+ s carcinoma 3/2 NE 2+ s carcinoma 3/3 NE 2+ s carcinoma 3/3 NE 4+ s carcinoma 3/3 NE 4+ s carcinoma 3/3 NE 4+ s carcinoma 3/3 N 4+ 34 S carcinoma 3/3 NE n 35 S carcinoma 3/3 NE 4+ 36 S carcinoma 3/3 NE 4+ 37 S carcinoma 3/3 NE 4+ 38 s carcinoma 3/3 N 4+ 39 s carcinoma 3/2 NE 2+ 40 s carcinoma 3/3 NE 4+ 41 s carcinoma 3/2 NE 4+ 42 M carcinoma 1/2 N n 43 M carcinoma 2/2 NE 4+ 44 M carcinoma 2/2 N 4+ 45 M carcinoma 3/1 NE n 46 M carcinoma 3/2 NE 4+ 47 M carcinoma 3/2 NE n 48 M carcinoma 3/3 NE n 49 E carcinoma 2/3 N 4+ 50 E carcinoma 3/2 NE 4+ 51 E carcinoma 3/3 NE 4+ 52 C carcinoma 1/3 N 4+ 53 C carcinoma 1/1 N . 4+ _5_4 C carcinoma 3/2 P 4+ a S, serous; M, mucinous; E, endometrioid; C, clear cell; b LN, lymph node metastasis; P, positive; N, negative; NE, not examined; c n, normal range = mean +2SD; 2+, mean +2SD to +4SD; 4+, mean +4SD or greater. TABLE 6 Overexpression of hepsin in normal ovaries and ovarian tumors Ijφfi N Hepsin Ratio of Hepsin Overexpression to β-tnbulin Normal 1 0 0 (0%) 0.06 ± 0.05 LMP 1 2 7 (58.3%) 0.26 ± 0.19 S erous 7 6 (85.7%) 0.34 ± 0.20 Mucinous 5 1 (20.0%) 0.14 + 0.12 Carcinomous 3 2 27 (84.4%) 0.46 ± 0.29 S erous 1 9 18 (94.7%) 0.56 + 0.32 Mucinous 7 3 (42.9%) 0.26 ± 0.22 Endometrioid 3 3 (100%) 0.34 ± 0.01 Clear Cell 3 3 (1 00% 0.45 + 0.0R EXAMPLE 14 Expression of SCCE and PUMP-1 Studies using both SCCE-specific primers (Figure 8) and PUMP-specific primers (Figure 9) indicate overexpression of these proteases in ovarian carcinomas. EXAMPLE 15 Summary of known proteases detected herein Most of the proteases described herein were identified from the sense-His/antisense-Ser primer pair, yielding a 500 bp PCR product (Figure 1, Lane 4). Some of the enzymes are familiar, a short summary of each follows. H p in Hepsin is a trypsin-like serine protease cloned from hepatoma cells. Hepsin is an extracellular protease (the enzyme includes a secretion signal sequence) which is anchored in the plasma membrane by its amino terminal domain, thereby exposing its catalytic domain to the extracellular matrix. Hepsin has also been shown to be expressed in breast cancer cell lines and peripheral nerve cells. Hepsin has never before been associated with ovarian carcinoma. Specific primers for the hepsin gene were synthesized and the expression of hepsin examined using Northern blots of fetal tissue and ovarian tissue (both normal and ovarian carcinoma) . Figure 10A shows that hepsin was expressed in ovarian carcinomas of different histologic types, but not in normal ovary. Figure 10B shows that hepsin was expressed in fetal liver and fetal kidney as anticipated, but at very low levels or not at all in fetal brain and lung. Figure 10C shows that hepsin overexpression is n o t observed in normal adult tissue. Slight expression above the background level is observed in the adult prostate. The mRNA identified in both Northern blots was the appropriate size for the hepsin transcript. The expression of hepsin was examined in 1 0 normal ovaries and 44 ovarian tumors using specific primers to β- tubulin and hepsin in a quantitative PCR assay, and found it to b e linear over 35 cycles. Expression is presented as the ratio of 32 P- hepsin band to the internal control, the 32 P- β-tubulin band. Hepsin expression was investigated in normal (N) , mucinous (M) and serous (S) low malignant potential (LMP) tumors and carcinomas (CA). Figure 11A shows quantitative PCR of hepsin and internal control β-tubulin. Figure 11B shows the ratio o f hepsin: β-tubulin expression in normal ovary, LMP tumor, and ovarian carcinoma. It was observed that Hepsin mRNA expression levels were significantly elevated in LMP tumors, (p < 0.005) and carcinomas (p < 0.0001) compared to levels in normal ovary. All 1 0 cases of normal ovaries showed a relatively low level of hepsin mRNA expression. Hepsin mRNA is highly overexpressed in most histopathologic types of ovarian carcinomas including some low malignant potential tumors (see Figures 11A & 11B). Most noticeably, hepsin is highly expressed in serous, endometrioid and clear cell tumors tested. It is highly expressed in some mucinous tumors, but it is not overexpressed in the majority of such tumors. Stratum corneum chymotrypsin enzyme (SCCE) The PCR product identified was the catalytic domain of the sense-His/antisense-Ser of the stratum corneum chymotrypsin enzyme. This extracellular protease was cloned, sequenced and shown to be expressed on the surface of keratinocytes in the epidermis. Stratum corneum chymotrypsin enzyme is a chymotrypsin-like serine protease whose function is suggested to b e in the catalytic degradation of intercellular cohesive structures in the stratum corneum layer of the skin. This degradation allows continuous shedding (desquamation) of cells from the skin surface. The subcellular localization of stratum corneum chymotrypsin enzyme is in the upper granular layer in the stratum corneum of normal non-palmoplantar skin and in the cohesive parts of hypertrophic plantar stratum corneum. Stratum corneum chymotrypsin enzyme is exclusively associated with the stratum corneum and has not so far been shown to be expressed in any carcinomatous tissues. Northern blots were probed with the PCR product t o determine expression of stratum corneum chymotrypsin enzyme in fetal tissue and ovarian carcinoma (Figures 12A & 12B). Noticeably, detection of stratum corneum chymotrypsin enzyme messenger RNA on the fetal Northern was almost non-existent (a problem with the probe or the blot was excluded by performing the proper controls) . A faint band appeared in fetal kidney. On the other hand, stratum corneum chymotrypsin enzyme mRNA is abundant in the ovarian carcinoma mRNA (Figure 12B). Two transcripts of the correct size are observed for stratum corneum chymotrypsin enzyme. The s ame panel of cDNA used for hepsin analysis was used for stratum corneum chymotrypsin enzyme expression. No stratum corneum chymotrypsin enzyme expression was detected in the normal ovary lane of the Northern blot. A comparison of all candidate genes, including a loading marker (β- tubulin), was shown to confirm that this observation was not a result of a loading bias. Quantitative PCR using stratum corneum chymotrypsin enzyme primers, along with β-tubulin internal control primers, confirmed the overexpression of stratum corneum chymotrypsin enzyme mRNA in carcinoma of the ovary with n o expression in normal ovarian tissue (Figure 13). Figure 13A shows a comparison using quantitative PCR of stratum corneum chymotrypsin enzyme cDNA from normal ovary and ovarian carcinomas. Figure 13B shows the ratio of stratum corneum chymotrypsin enzyme to the β-tubulin internal standard in 10 normal and 44 ovarian carcinoma tissues. Again, it is observed that stratum corneum chymotrypsin enzyme is highly overexpressed in ovarian carcinoma cells. It is also noted that some mucinous tumors overexpress stratum corneum chymotrypsin enzyme, but the majority do not. Protease M Protease M was identified from subclones of the His--ser primer pair. This protease was first cloned by Anisowicz, et al., [Molecular Medicine, 2, 624-636 (1996)] and shown to b e overexpressed in carcinomas. A preliminary evaluation indicates that this enzyme is overexpressed in ovarian carcinoma (Figure 14). Cofar.tor J and Complement factor Several serine proteases associated with the coagulation pathway were also subcloned. Examination of normal and ovarian carcinomas by quantitative PCR for expression of these enzymes, it was noticeable that this mRNA was not clearly overexpressed in ovarian carcinomas when compared to normal ovarian tissue. It should be noted that the same panel of tumors was used for the evaluation of each candidate protease. EXAMPLE S Summary of previously unknown proteases detected herein TA BG- l ?. TADG-12 was identified from the primer pairs, sense- His/antisense-Asp (see Figure 1, Lanes 1 & 2). Upon subcloning both PCR products in lane 2, the 200 bp product had a unique protease-like sequence not included in GenBank. This 200 b p product contains many of the conserved amino acids common for the His-Asp domain of the family of serine proteins. The second an d larger PCR product (300 bp) was shown to have a high degree o f homology with TADG-12 (His-Asp sequence), but also contained approximately 100 bp of unique sequence. Synthesis of specific primers and the sequencing of the subsequent PCR products fro m three different tumors demonstrated that the larger PCR produc t (present in about 50% of ovarian carcinomas) includes an insert o f about 100 bp near the 5' end (and near the histidine) of th e sequence. This insert may be a retained genomic intron because o f the appropriate position of splice sites and the fact that the insert does not contain an open reading frame (see Figure 15). This suggests the possibility of a splice site mutation which gives rise t o retention of the intron, or a translocation of a sequence into th e TADG-12 gene in as many as half of all ovarian carcinomas. TA DCr- n and TA DG- 14 Specific primers were synthesized for TADG-13 an d TADG-14 to evaluate expression of genes in normal and ovarian carcinoma tissue. Northern blot analysis of ovarian tissues indicates the transcript for the TADG-14 gene is approximately 1.4 kb and is expressed in ovarian carcinoma tissues (Figure 16A) with n o noticeable transcript presence in normal tissue. In quantitative PCR studies using specific primers, increased expression of TADG-14 in ovarian carcinoma tissues was noted compared to a normal ovary (Figure 16B). The presence of a specific PCR product for TADG-14 in both an HeLa library and an ovarian carcinoma library was also confirmed. Several candidate sequences corresponding to TADG-14 have been screened and isolated from the HeLa library. Clearly from sequence homology, these genes fit into the family of serine proteases. TADG-13 and -14 are, however, heretofore undocumented genes which the specific primers of the invention allow to be evaluated in normal and tumor cells, and with which the presence or absence of expression of these genes is useful in the diagnosis or. treatment selection for specific tumor types. PUMP- 1 In a similar strategy using redundant primers to metal binding domains and conserved histidine domains, a differentially expressed PCR product identical to matrix metallo-protease 7 (MMP- 7) was identified, herein called PUMP-1. Using specific primers for PUMP-1, PCR produced a 250 bp product for Northern blot analysis. PUMP-1 is differentially expressed in fetal lung and kidney tissues. Figure 17A shows the expression of PUMP-1 in human fetal tissue, while no transcript could be detected in either fetal brain or fetal liver. Figure 17B compares PUMP-1 expression in normal ovary and carcinoma subtypes using Northern blot analysis. Notably, PUMP-1 is expressed in ovarian carcinoma tissues, and again, the presence of a transcript in normal tissue was no t detected. Quantitative PCR comparing normal versus ovarian carcinoma expression of the PUMP-1 mRNA indicates that this gene is highly expressed in serous carcinomas, including most low malignant serous tumors, and is, again, expressed to a lesser extent in mucinous tumors (see Figures 18A & 18B). PUMP-1, however, is so far the protease most frequently found overexpressed in mucinous tumors (See Table 7). Cathepsin-L Using redundant cysteine protease primers to conserved domains surrounding individual cysteine and histidine residues, the cathepsin-L protease was identified in several serous carcinomas . An initial examination of the expression of cathepsin L in normal and ovarian tumor tissue indicates that transcripts for the cathepsin-L protease are present in both normal and tumor tissues (Figure 19). However, its presence or absence in combination with other proteases of the present invention permits identification of specific tumor types and treatment choices. Discussi on Redundant primers to conserved domains of serine, metallo-, and cysteine proteases have yielded a set of genes whose mRNAs are overexpressed in ovarian carcinoma. The genes which are clearly overexpressed include the serine proteases hepsin, stratum corneum chymotrypsin enzyme, protease M TADG12, TADG14 and the metallo-protease PUMP-1 (see Figure 19 and Table 7). Northern blot analysis of normal and ovarian carcinoma tissues, summarized in Figure 14, indicated overexpression of hepsin, stratum corneum chymotrypsin enzyme, PUMP-1 and TADG-14. A β- tubulin probe to control for loading levels was included. TABLE 7 Overexpression of Proteases in Ovarian Tumors Typ e _N_ Hep si n SCCE Pump- Protease M Normal 1 0 0% (0/10) 0% (0/10) 0% (0/10) 0% (0/10) LMP 12 58.3% (7/12) 66.7% (8/12) 75.0% (9/12) 75% (9/12) serous 7 85.7% (6/7) 85.7% (6/7) 85.7% (6/7) 100% (7/7) mucinous 5 20.0% (1/5) 40.0% (2/5) 60% (3/5) 40.0%(2/5) Carcinoma 32 84.4% (27/32) 78.1 % (25/32) 81.3% (26/32) 90.6% (29/32 serous 1 9 94.7 ( 18/19) 89.5%( 17/19) 78.9% (15/19) 94.7% (18/19 mucinous 7 42.9%(3/7) 28.696(2/7) 71.4% (5/7) 85.7% (6/7) endometr. 3 100% (3/3) 100%(3/3) 100% (3/3) 100% (3/3) clear cell 3 100% (3/3) 100% (3/3) 100% (3/3) 67.7% (2/3) For the most part, these proteins previously have no t been associated with the extracellular matrix of ovarian carcinoma cells. No panel of proteases which might contribute to the growth, shedding, invasion and colony development of metastatic carcinoma has been previously described, including the three new candidate serine proteases which are herein disclosed. The establishment of an extracellular protease panel associated with either malignant growth or malignant potential offers the opportunity for th e identification of diagnostic or prognostic markers and for therapeutic intervention through inhibition or down regulation o f these proteases. The availability of the instant gene-specific primers coding for the appropriate region of tumor specific proteases allows for the amplification of a specific cDNA probe using Northern and Southern analysis, and their use as markers to detect the presence of the cancer in tissue. The probes also allow more extensive evaluation of the expression of the gene in normal ovary versus low malignant potential tumor, as well as both high- and low- stage carcinomas. The evaluation of a panel of fresh frozen tissue from all the carcinoma subtypes (Table 4) allowed the determination o f whether a protease is expressed predominantly in early stage disease or within specific carcinoma subtypes. It was also determined whether each gene's expression is confined to a particular stage in tumor progression and/or is associated with metastatic lesions . Detection of specific combinations of proteases is an identifying characteristic of the specific tumor types and yields valuable information for diagnoses and treatment selection. Particular tumor types may be more accurately diagnosed by the characteristic expression pattern of each specific tumor. EXAMPLE 17 Eeptide ranking For vaccine or immune stimulation, individual 9-mers t o 11-mers of the hepsin protein were examined to rank the binding of individual peptides to the top 8 haplotypes in the general population (Parker et al., (1994)). The computer program used for this analyses can be found at <http://www- bimas.dcrt.nih.gov/molbio/hla_bind/>. Table 8 shows the peptide ranking based upon the predicted half-life of each peptide 5 s binding to a particular HLA allele. A larger half-life indicates a stronger association with that peptide and the particular HLA molecule. The hepsin peptides that strongly bind to an HLA allele are putative immunogens, and are used to innoculate an individual against hepsin. TABLE 8 Hepsin peptide ranking HLA Type Predicted SEQ & Ranking Start Peptide Dis ciation ! -, TD No. HLA A0201 1 170 SLGRWPWQV 521.640 28 2 191 SLLSGDWVL 243.051 29 3 229 GLQLGVQAV 159.970 30 4 392 KVSDFREWI 134.154 31 5 308 VLQEARVPI 72.717 32 6 130 RTIEVISVC 71.069 33 ' 7 98 ALTHSELDV 69.552 34 8 211 VLSRWRVFA 46.451 35 9 26 TIIITAIGA 31.249 36 10 284 ALVDGKICT 30.553 37 11 145 FLAAICQDC 22.853 38 12 192 LLSGDWVLT 21.536 39 13 20 ALTAGTLLL 21.362 40 14 259 ALVHLSSPL 21.362 41 15 277 CLPAAGQAL 21.362 42 16 230 LQLGVQAW 18.186 43 17 268 PLTEYIQPV 14.429 44 18 31 AIGAASWAI 10.759 45 19 285 LVDGKICTV 9.518 46 20 27 LLLTAIGAA 9.343 47 HLA A0205 1 191 SLLSGDWVL 25.200 48 2 163 LVGGRDTSL 23.800 49 3 392 KVSDFREWI 18.000 50 4 64 MVFDKTEGT 15.300 51 5 236 AWYHGGYL 14.000 52 6 55 QVSSADARL 14.000 53 7 130 RTIRVTSVC 9.000 54 8 230 LQLGVQAW 8.160 55 9 20 ALTAGΠI 7.000 56 10 259 ALVHLSSPL 7.000 57 11 277 CLPAAGQAL 7.000 58 12 17 KVAALTAGT 6.000 59 13 285 LVDGKICTV 5.440 60 14 308 VLQEARVPI 5.100 61 15 27 LTI AIGAA 5.100 62 16 229 GLQLGVQAV 4.000 63 17 313 RVPΠSNDV 4.000 64 18 88 LSCEEMGFL 3.570 65 19 192 LLSGDWVLT 3.400 66 20 284 ALVDGKICT 3.000 61 61 HLAA1 1 89 SCEEMCΪ R 45.000 68 2 58 SADARLMVF 25.000 69 3 393 VSDFREWIF 7.500 70 4 407 HSEASGMVT 6.750 71 5 137 VCDCPRGRF 5.000 72 6 269 LTEYIQPVC 4.500 73 7 47 DQEPLYPVQ 2.700 74 8 119 CVDEGRLPH 2.500 75 99 6688 KKTTEEGGTTWWRRLLLL 22..225500 76 10 101 HSELDVRTA 1.350 77 11 250 NSEENSNDI 1.350 78 12 293 VTGWGNTQY 1.250 79 13 231 QLGVQAWY 1.000 80 1144 110033 EELLDDVVRRTTAAGGAA 11..000000 81 15 378 GTGCALAQK 1.000 82 16 358 VCEDSISRT 0.900 83 17 264 SSFLPLTEY 0.750 84 18 87 GLSCEEMGF 0.500 85 1199 227722 Y YIIQQPPVVCCLLPPAA 00..550000 86 20 345 GIDACQGDS 0.500 87 HLA A24 1 301 YYGQQAGVL 200.000 88 2 238 VYHGGYLPF 100.000 89 33 220044 CCFFPPEERRNNRRVVLL 3366..000000 90 4 117 FFCVDEGRL 20.000 91 5 124 RLPHTQRLL 12.000 92 6 80 RSNARVAGL 12.000 93 7 68 KTLiGTWRLLl 2.000 94 8 340 GYPEGGIDA 9.000 95 9 242 GYLPFRDPN 9.000 96 10 51 LYPVQVSSA 7.500 97 11 259 ALVHLSSPL 7.200 98 12 277 CLPAAGQAL 7.200 99 13 191 SLLSGDWVL 6.000 100 14 210 RVLSRWRVF 6.000 101 15 222 VAQASPHGL 6.000 102 16 236 AWYHGGYL 6.000 103 17 19 AALTAGTLL 6.000 104 18 36 SWAΓVAVLL 5.600 105 19 35 ASWAΓVAVL 5.600 106 20 300 QYYGQQAGV 5.600 107 ΪLAB7 1 363 ISRTPRWRL 90.000 108 2 366 TPRWRLCGI 80.000 109 3 236 AWYHGGYL 60.000 110 4 13 CSRPKVAAL 40.000 111 5 179 SLRYDGAHL 40.000 112 6 43 LLRSDQEPL 40.000 113 7 19 AALTAGTLL 36.000 114 8 55 QVSSADARL 20.000 115 9 163 LVGGRDTSL 20.000 116 10 140 CPRGRFLAA 20.000 117 11 20 ALTAGTLLL 12.000 118 12 409 EASGMVTQL 12.000 119 13 259 ALVHLSSPL 12.000 120 14 35 ASWATVAVL 12.000 121 15 184 GAHLCGGSL 12.000 122 16 18 VAALTAGTL 12.000 123 17 222 VAQASPHGL 12.000 124 18 224 QASPHGLQL 12.000 125 19 265 SPLPLTEYI 8.000 126 20 355 GPFVCEDSI 8.00 127 HLAB8 1 13 CSRPKVAAL 80.000 128 2 366 TPRWRLCGI 80.000 129 3 140 CPRGRFLAA 16.000 130 4 152 DCGRRKLPV 4.800 131 5 363 ISRTPRWRL 4.000 132 6 163 LVGGRDTSL 4.000 133 7 331 QIKPKMFCA 4.000 134 8 80 RSNARVAGL 2.000 135 9 179 SLRYDGAHL 1.600 136 10 43 LLRSDQEPL 1.600 137 11 409 EASGMVTQL 1.600 138 12 311 EARVPΠSN 0.800 139 13 222 VAQASPHGL 0.800 140 14 19 AALTAGTLL 0.800 141 15 18 VAALTAGTL 0.800 142 16 184 GAHLCGGSL 0.800 143 17 224 QASPHGLQL 0.800 144 18 82 NARVAGLSC 0.800 145 19 204 CFPERNRVL 0.600 146 20 212 LSRWRVFAG 0.400 147 HLA B2702 1 172 GRWPWQVSL 300.000 148 2 44 LRSDQEPLY 200.00 149 3 155 RRKLPVDRI 180.000 150 4 213 SRWRVFAGA 100.000 151 5 166 GRDTSLGRW 100.000 152 6 369 WRLCGIVSW 100.000 153 7 180 LRYDGAHLC 100.000 154 8 96 LRALTHSEL 60.000 155 9 396 FREWIFQAI 60.000 156 10 123 GRLPHTQRL 60.000 157 11 207 ERNRVLSRW 30.000 158 12 209 NRVLSRWRV 20.000 159 13 14 SRPKVAALT 20.000 160 14 106 VRTAGANGT 20.000 161 15 129 QRLLEVSV 20.000 162 16 349 CQGDSGGPF 20.000 163 17 61 ARLMVFDKT 20.000 164 18 215 WRVFAGAVA 20.000 165 19 143 GRFLAAICQ 10.000 166 20 246 FRDPNSEEN 10.000 167 HLA B4403 1 132 LEVISVCDC 36.000 168 2 91 EEMGFLRAL 18.000 169 3 264 SSPLPLTEY 13.500 170 4 310 QEARVPΠS 12.000 171 5 319 NDVCNGADF 10.000 172 6 4 KEGGRTVPC 9.000 173 7 25 1 SEENSNDIA 8.000 174 8 256 NDIALVHLS 7.500 175 9 294 TGWGNTQYY 6.750 176 1 0 36 1 DSISRTPRW 6.750 177 1 1 235 QAWYHGGY 6.000 178 1 2 1 09 AGANGTSGF 6.000 179 1 3 270 TEYIQPVCL 6.000 180 1 4 1 74 WPWQVSLRY 4.500 181 1 5 293 VTGWGNTQY 4.500 182 1 6 6 9 TEGTWRLLC 4.000 183 1 7 9 0 CEEMGFLRA 4.000 184 1 8 252 EENSNDIAL 4.000 185 1 9 4 8 QEPLYPVQV 4.000 186 7.0 1 02 SET DVRTAG 3 .600 187 Any patents or publications mentioned in this specification are indicative of the levels of those skilled in the art t o which the invention pertains. Further, these patents and publications are incorporated by reference herein to the s ame extent as if each individual publication was specifically and individually indicated to be incorporated by reference. One skilled in the art will appreciate readily that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those objects, ends and advantages inherent herein. The present examples, along with the methods, procedures, treatments, molecules, and specific compounds described herein are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention as defined by the scope of the claims .

Claims: WHAT IS CLAIMED IS: 1 . A method of diagnosing cancer in an individual, comprising the steps of: ( a) obtaining a biological sample from an individual; and ( b ) detecting hepsin in said sample, wherein th e presence of hepsin in said sample is indicative of the presence o f cancer in said individual, whereas the absence of hepsin in said sample is indicative of the absence of cancer in said individual. 2. The method of claim 1, wherein said biological sample is selected from the group consisting of blood, urine, saliva, tears, interstitial fluid, ascites fluid, tumor tissue biopsy and circulating tumor cells. 3 . The method of claim 1, wherein said detection o f said hepsin is by means selected from the group consisting of Northern blot, Western blot, PCR, dot blot, ELIZA sandwich assay, radioimmunoassay, DNA array chips and flow cytometry. 4. The method of claim 1, wherein said cancer is selected from the group consisting of ovarian, breast, lung, colon, prostate and others in which hepsin is overexpressed. 5 . A method for detecting malignant hyperplasia in a biological sample, comprising the steps of: ( a ) isolating mRNA from said sample; and ( b ) detecting hepsin mRNA in said sample, wherein th e presence of said hepsin mRNA in said sample is indicative of th e presence of malignant hyperplasia, wherein the absense of said hepsin mRNA in said sample is indicative of the absence o f malignant hyperplasia. 6 . The method of claim 5, further comprising the step of: comparing said hepsin mRNA to reference information, wherein said comparison provides a diagnosis of said malignant hyperplasia. 7 . The method of claim 5 further comprising the step of: comparing said hepsin mRNA to reference information, wherein said comparison determines a treatment of said malignant hyperplasia. 8 . The method of claim 5, wherein said detection of said hepsin mRNA is by PCR amplification. 9 . The method of claim 8, wherein said PCR amplification uses primers selected from the group consisting of SEQ ID No. 8 and SEQ ID No. 9. 1 0. The method of claim 5, wherein said biological sample is selected from the group consisting of blood, urine, saliva, tears, interstitial fluid, ascites fluid, tumor tissue biopsy and circulating tumor cells. 1 1 . A method for detecting malignant hyperplasia in a biological sample, comprising the steps of: ( a) isolating protein from said sample; and ( b ) detecting hepsin protein in said sample, wherein the presence of said hepsin protein in said sample is indicative o f the presence of malignant hyperplasia, wherein the absense of said hepsin protein in said sample is indicative of the absence of malignant hyperplasia. 1 2. The method of claim 11, further comprising th e step of: comparing said hepsin protein to reference information, wherein said comparison provides a diagnosis of said malignant hyperplasia. 13 . The method of claim 11, further comprising the step of: comparing said hepsin protein to reference information, wherein said comparison determines a treatment of said malignant hyperplasia. 14. The method of claim 11, wherein said detection is by immuno affinity to an antibody, wherein said antibody is specific for hepsin. 15 . The method of claim 11, wherein said biological sample is selected from the group consisting of blood, urine, saliva, tears, interstitial fluid, ascites fluid, tumor tissue biopsy an d circulating tumor cells. 16. A method of inhibiting expression of endogenous hepsin in a cell, comprising the step of: introducing a vector into a cell, wherein said vector comprises a hepsin gene in opposite orientation operably linked t o elements necessary for expression, wherein expression of said vector in said cell produces hepsin antisense mRNA, wherein said hepsin antisense mRNA hybridizes to endogenous hepsin mRNA, thereby inhibiting expression of endogenous hepsin in said cell. 17. A method of inhibiting hepsin protein in a cell, comprising the step of: introducing an antibody into a cell, wherein said antibody is specific for a hepsin protein or a fragment thereof, wherein binding of said antibody to said hepsin protein inhibits said hepsin protein. 1 8. A method of targeted therapy to an individual, comprising the step of: administering a compound to an individual, wherein said compound has a targeting moiety and a therapeutic moiety, wherein said targeting moiety is specific for hepsin. 1 9. The method of claim 18, wherein said targeting moiety is selected from the group consisting of an antibody specific for hepsin and a ligand or ligand binding domain that binds hepsin. 20. The method of claim 18, wherein said therapeutic moiety is selected from the group consisting of a radioisotope, a toxin, a chemotherapeutic agent, an immune stimulant and a cytotoxic agent. 21 . The method of claim 18, wherein said individual suffers from ovarian cancer, lung cancer, prostate cancer, colon cancer and other cancers in which hepsin is overexpressed. 22. A method of vaccinating an individual against hepsin, comprising the step of: inoculating an individual with a hepsin protein o r fragment thereof, wherein said hepsin protein or fragment thereof lack hepsin protease activity, wherein said inoculation with said hepsin protein or fragment thereof elicits an immune response in said individual, thereby vaccinating said individual against hepsin. 23 . The method of claim 22, wherein said individual has cancer, is suspected of having cancer or is at risk of getting cancer. 24. The method of claim 22, wherein said hepsin fragment is selected from the group consisting of a 9-residue fragment up to a 20-residue fragment. 25 . The method of claim 24, wherein said 9-residue fragment is selected from the group consisting of SEQ LD Nos. 28 , 29, 30, 31, 88, 89, 108, 109, 128, 129, 148, 149, 150, 151, 152, 1 53 and 154. 26. A method of producing immune-activated cells directed toward hepsin, comprising the steps of: exposing dendritic cells to a hepsin protein or fragment thereof, wherein said hepsin protein or fragment thereof lacks hepsin protease activity, wherein said exposure to said hepsin protein or fragment thereof activates said dendritic cells, thereby producing immune- activated cells directed toward hepsin. 27. The method of claim 26, wherein said immune- activated cells are selected from the group consisting of B-cells, T- cells and dendrites. 28 . The method of claim 26, wherein said hepsin fragment is selected from the group consisting of a 9-residue fragment up to a 20-residue fragment. 29 . The method of claim 28, wherein said 9-residue fragment is selected from the group consisting of SEQ ID Nos. 28 , 29, 30, 31, 88, 89, 108, 109, 128, 129, 148, 149, 150, 151, 152, 1 5 3 and 154. 30. The method of claim 26, wherein said dendritic cells are isolated from an individual prior to said exposure, wherein said activated dendritic cells are reintroduced into said individual subsequent to said exposure. 3 1 . The method of claim 30, wherein said individual has a cancer, is suspected of having a cancer or is at risk of getting a cancer. 32. An immunogenic composition, comprising a n immunogenic fragment of a hepsin protein and an appropriate adjuvant. 33 . The immunogenic composition of claim 32 , wherein said hepsin fragment is selected from the group consisting of a 9-residue fragment up to a 20-residue fragment. 34. The immunogenic composition of claim 33 , wherein said 9-residue fragment is selected from the group consisting of SEQ ID Nos. 28, 29, 30, 31, 88, 89, 108, 109, 128, 129, 148, 149, 150, 151, 152, 153 and 154. 35 . An oligonucleotide having a sequence complementary to SEQ ID No.188. 36. A composition comprising the oligonucleotide of claim 35 and a physiologically acceptable carrier. 37. A method of treating a neoplastic state in a n individual in need of such treatment, comprising the step of: ( a) administering to said individual an effective do s e of the oligonucleotide of claim 35. 3 8. The method of claim 37, wherein said neoplastic state is selected from the group consisting of ovarian cancer, breast cancer, lung cancer, colon cancer, prostate cancer and other cancers in which hepsin is overexpressed. 39. A method of screening for compounds that inhibit hepsin activity, comprising the steps of: ( a) contacting a sample with a compound, wherein said sample comprises hepsin protein; and ( b ) assaying for hepsin protease activity, wherein a decrease in said hepsin protease activity in the presence of said compound relative to hepsin protease activity in the absence of said compound is indicative of a compound that inhibits hepsin activity.

Inventors: O'BRIEN TIMOTHY J, O'BRIEN, TIMOTHY, J.
Applicants: TRUSTEES OF THE UNIVERSITY OF, THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
Application year: 2001
Main classification: A61K38
IPC codes: A61K39, C07K14, C12Q1, G01N33, G01N37